纳入重要临床变量对囊性纤维化和慢阻肺肺分配评分准确性的影响
该多中心回顾性研究利用移植受者科学登记和囊性纤维化基金会患者登记匹配数据,重新计算包含CF特异性变量的LAS模型。结果显示伯克霍尔德菌属、长期住院、大咯血和FEV1显著下降增加CF候选者等待期死亡风险,而COPD候选者FEV1相对下降≥10%与等待期死亡风险增加相关。结论是加入CF特异性变量提高了CF候选者的区分度并使COPD候选者获益。
要点
- CF候选者中伯克霍尔德菌属、住院29-42天、大咯血和FEV1下降≥30%增加等待期死亡风险。
- COPD候选者FEV1相对下降≥10%与等待期死亡风险增加相关(HR 2.6)。
- 加入CF特异性变量提高了CF候选者LAS评分的区分度并增加了COPD候选者的移植优先级。
核心结论
- 加入CF特异性变量改善了等待名单上CF候选者的区分度,并使COPD候选者获益。
研究设计与样本
- 多中心、回顾性、基于人群的研究,采用确定性匹配算法链接移植受者科学登记与囊性纤维化基金会患者登记。
- 纳入2011年1月1日至2014年12月31日所有12岁及以上肺移植等待名单候选者共9,043例,其中CF 1,020例。
- 纳入2011至2014年间6,110例肺移植受者,其中CF 677例。
主要发现
- CF候选者中任何伯克霍尔德菌属(HR 2.8;95%CI 1.2-6.6)、住院29-42天(HR 2.8;95%CI 1.3-5.9)、大咯血(HR 2.1;95%CI 1.1-3.9)、12个月内FEV1相对下降≥30%(HR 1.7;95%CI 1.0-2.8)增加等待期死亡风险。
- CF候选者中肺急性加重时间15-28天(HR 1.8;95%CI 1.1-2.9)增加移植后死亡风险。
- COPD候选者中FEV1相对下降≥10%与等待期死亡风险增加相关(HR 2.6;95%CI 1.2-5.4)。
- CF患者的LAS评分和排名变异性增加,COPD候选者的移植优先级增加,其他诊断组的可及性未变。
临床怎么用
- 对于CF肺移植候选者,评估时应关注伯克霍尔德菌属感染、近期长期住院、大咯血及FEV1快速下降等增加等待期死亡风险的变量。
- 对于COPD肺移植候选者,FEV1相对下降≥10%可提示等待期死亡风险增加,应考虑纳入优先级评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Clinical variables associated with shortened survival in patients with advanced-stage cystic fibrosis (CF) are not included in the lung allocation score (LAS).Objectives: To identify variables associated with wait-list and post-transplant mortality for CF lung transplant candidates using a novel database and to analyze the impact of including new CF-specific variables in the LAS system.Methods: A deterministic matching algorithm identified patients from the Scientific Registry of Transplant Recipients and the Cystic Fibrosis Foundation Patient Registry. LAS wait-list and post-transplant survival models were recalculated using CF-specific variables. This multicenter, retrospective, population-based study of all lung transplant wait-list candidates aged 12 years or older from January 1, 2011, to December 31, 2014, included 9,043 patients on the lung transplant waiting list and 6,110 lung transplant recipients between 2011 and 2014, comprising 1,020 and 677 with CF, respectively.Measurements and Main Results: Measured outcomes were changes in LAS and lung allocation rank. For CF candidates, any Burkholderia sp. (hazard ratio [HR], 2.8; 95% confidence interval [CI], 1.2-6.6), 29-42 days hospitalized (HR 2.8; CI 1.3-5.9), massive hemoptysis (HR 2.1; CI 1.1-3.9), and relative drop in FEV1 ≥30% over 12 months (HR 1.7; CI 1.0-2.8) increased wait-list mortality risk; pulmonary exacerbation time 15-28 days (1.8; 1.1-2.9) increased post-transplant mortality risk. A relative drop in FEV1 ≥10% in chronic obstructive pulmonary disease (COPD) candidates was associated with increased wait-list mortality risk (HR 2.6; CI 1.2-5.4). Variability in LAS score and rank increased in patients with CF. Priority for transplant increased for COPD candidates. Access did not change for other diagnosis groups.Conclusions: Adding CF-specific variables improved discrimination among wait-listed CF candidates and benefited COPD candidates.
引用
- Lehr CJ, Skeans M, Dasenbrook E, et al. Effect of Including Important Clinical Variables on Accuracy of the Lung Allocation Score for Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2019. PMID: 31199166. doi:10.1164/rccm.201902-0252OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。